Conquering Diseases

Experimental Treatment for Children with Acute Myeloid Leukemia and Down Syndrome

Description

This study is looking at using different experimental treatment methods for children diagnosed with Acute Myeloid Leukemia (AML) and Down Syndrome (DS) based on how well they respond to their first treatment.

Overview

This study is trying to determine the best amount of treatment patients should receive by dividing patients into standard risk and high risk subgroups based on how well they responded to their first treatment. Standard risk patients will receive less treatment than children with DS AML receive today, in the hope that they can be successfully treated with less treatment, decreasing side effects. High risk patients will be treated with higher doses of chemotherapy.

What we're hoping for

We hope to find out if standard risk DS AML can be treated with less treatment and still have successful outcomes and if subjects with high risk DS AML can be successfully treated with stronger chemotherapy.

Additional Information

ClinicalTrials.gov Identifier: NCT02521493

 Principal Investigator

Christopher  Keuker, MD

UMass Memorial Health Care

 Study Contact

Pediatrics Hem-Oncology  Research Center

774-441-8083

pedihemonc@umassmemorial.org

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989